173 related articles for article (PubMed ID: 12039701)
21. Clinical characteristics and effects of GH replacement therapy in adults with childhood-onset craniopharyngioma compared with those in adults with other causes of childhood-onset hypothalamic-pituitary dysfunction.
Yuen KC; Koltowska-Häggström M; Cook DM; Fox JL; Jönsson PJ; Geffner ME; Abs R
Eur J Endocrinol; 2013 Oct; 169(4):511-9. PubMed ID: 23904277
[TBL] [Abstract][Full Text] [Related]
22. Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: data from the Pfizer International Metabolic Database.
Maiter D; Abs R; Johannsson G; Scanlon M; Jönsson PJ; Wilton P; Koltowska-Häggström M
Eur J Endocrinol; 2006 Aug; 155(2):253-60. PubMed ID: 16868138
[TBL] [Abstract][Full Text] [Related]
23. From isolated GH deficiency to multiple pituitary hormone deficiency: an evolving continuum - a KIMS analysis.
Klose M; Jonsson B; Abs R; Popovic V; Koltowska-Häggström M; Saller B; Feldt-Rasmussen U; Kourides I
Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S75-83. PubMed ID: 19684053
[TBL] [Abstract][Full Text] [Related]
24. GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence.
Arnold JR; Arnold DF; Marland A; Karavitaki N; Wass JA
Clin Endocrinol (Oxf); 2009 Mar; 70(3):435-8. PubMed ID: 19236640
[TBL] [Abstract][Full Text] [Related]
25. The impact of glucocorticoid replacement on bone mineral density in patients with hypopituitarism before and after 2 years of growth hormone replacement therapy.
Ragnar Agnarsson H; Johannsson G; Ragnarsson O
J Clin Endocrinol Metab; 2014 Apr; 99(4):1479-85. PubMed ID: 24423362
[TBL] [Abstract][Full Text] [Related]
26. The effect of growth hormone replacement in patients with hypopituitarism on pituitary tumor recurrence, secondary cancer, and stroke.
Jasim S; Alahdab F; Ahmed AT; Tamhane SU; Sharma A; Donegan D; Nippoldt TB; Murad MH
Endocrine; 2017 May; 56(2):267-278. PubMed ID: 27815769
[TBL] [Abstract][Full Text] [Related]
27. Non-functioning pituitary macroadenomas: Benefit from early growth hormone substitution after surgery.
Sauer N; Flitsch J; Doeing I; Dannheim V; Burkhardt T; Aberle J
Growth Horm IGF Res; 2014; 24(2-3):71-5. PubMed ID: 24726277
[TBL] [Abstract][Full Text] [Related]
28. The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database.
Spielhagen C; Schwahn C; Möller K; Friedrich N; Kohlmann T; Moock J; Kołtowska-Häggström M; Nauck M; Buchfelder M; Wallaschofski H
Growth Horm IGF Res; 2011 Feb; 21(1):1-10. PubMed ID: 21093334
[TBL] [Abstract][Full Text] [Related]
29. Overall and cause-specific mortality in GH-deficient adults on GH replacement.
Gaillard RC; Mattsson AF; Akerblad AC; Bengtsson BÅ; Cara J; Feldt-Rasmussen U; Koltowska-Häggström M; Monson JP; Saller B; Wilton P; Abs R
Eur J Endocrinol; 2012 Jun; 166(6):1069-77. PubMed ID: 22457236
[TBL] [Abstract][Full Text] [Related]
30. Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients.
Agha A; Walker D; Perry L; Drake WM; Chew SL; Jenkins PJ; Grossman AB; Monson JP
Clin Endocrinol (Oxf); 2007 Jan; 66(1):72-7. PubMed ID: 17201804
[TBL] [Abstract][Full Text] [Related]
31. Sheehan's syndrome: baseline characteristics and effect of 2 years of growth hormone replacement therapy in 91 patients in KIMS - Pfizer International Metabolic Database.
Kelestimur F; Jonsson P; Molvalilar S; Gomez JM; Auernhammer CJ; Colak R; Koltowska-Häggström M; Goth MI
Eur J Endocrinol; 2005 Apr; 152(4):581-7. PubMed ID: 15817914
[TBL] [Abstract][Full Text] [Related]
32. Baseline characteristics and effects of ten years of growth hormone (GH) replacement therapy in adults previously treated with pituitary irradiation.
Elbornsson M; Götherström G; Bengtsson BÅ; Johannsson G; Svensson J
Growth Horm IGF Res; 2013 Dec; 23(6):249-55. PubMed ID: 24103227
[TBL] [Abstract][Full Text] [Related]
33. Reviewing the safety of GH replacement therapy in adults.
Stochholm K; Johannsson G
Growth Horm IGF Res; 2015 Aug; 25(4):149-57. PubMed ID: 26117668
[TBL] [Abstract][Full Text] [Related]
34. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.
Drake WM; Coyte D; Camacho-Hübner C; Jivanji NM; Kaltsas G; Wood DF; Trainer PJ; Grossman AB; Besser GM; Monson JP
J Clin Endocrinol Metab; 1998 Nov; 83(11):3913-9. PubMed ID: 9814468
[TBL] [Abstract][Full Text] [Related]
35. The effects of growth hormone deficiency and replacement on glucocorticoid exposure in hypopituitary patients on cortisone acetate and hydrocortisone replacement.
Swords FM; Carroll PV; Kisalu J; Wood PJ; Taylor NF; Monson JP
Clin Endocrinol (Oxf); 2003 Nov; 59(5):613-20. PubMed ID: 14616886
[TBL] [Abstract][Full Text] [Related]
36. Nonfatal stroke, cardiac disease, and diabetes mellitus in hypopituitary patients on hormone replacement including growth hormone.
Holmer H; Svensson J; Rylander L; Johannsson G; Rosén T; Bengtsson BA; Thorén M; Höybye C; Degerblad M; Bramnert M; Hägg E; Edén Engström B; Ekman B; Norrving B; Hagmar L; Erfurth EM
J Clin Endocrinol Metab; 2007 Sep; 92(9):3560-7. PubMed ID: 17623762
[TBL] [Abstract][Full Text] [Related]
37. The effect of growth hormone substitution on cognitive performance in adult patients with hypopituitarism.
Oertel H; Schneider HJ; Stalla GK; Holsboer F; Zihl J
Psychoneuroendocrinology; 2004 Aug; 29(7):839-50. PubMed ID: 15177699
[TBL] [Abstract][Full Text] [Related]
38. [Long term treatment with growth hormone deficiency in adults].
Cabo D; Lecube A; Barrios M; Mesa J
Med Clin (Barc); 2011 May; 136(15):659-64. PubMed ID: 21411111
[TBL] [Abstract][Full Text] [Related]
39. Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy.
Frajese G; Drake WM; Loureiro RA; Evanson J; Coyte D; Wood DF; Grossman AB; Besser GM; Monson JP
J Clin Endocrinol Metab; 2001 Nov; 86(11):5172-5. PubMed ID: 11701673
[TBL] [Abstract][Full Text] [Related]
40. Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing's disease or non-functioning pituitary adenoma.
Webb SM; Mo D; Lamberts SW; Melmed S; Cavagnini F; Pecori Giraldi F; Strasburger CJ; Zimmermann AG; Woodmansee WW;
J Clin Endocrinol Metab; 2010 Feb; 95(2):630-8. PubMed ID: 20022992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
